Physician profile
Sandra Cotto
NPI 1598303885
$1,411.03
in general payments reported to CMS, 2019-2025
10 companies · $883 in 2025
The $883 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $24.48 · 2024: $504 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,411.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $542.93 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.77 | 2025 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $227.91 | 2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $121.83 | 2025 | Airsupra |
| Medtronic, INC. | $97.46 | 2024 | Intellis Adaptivestim |
| Amgen INC. | $72.30 | 2024-2025 | Repatha, Repatha, Otezla |
| Exact Sciences Corporation | $53.06 | 2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $24.48 | 2023 | |
| Shield Therapeutics INC | $20.30 | 2024 | |
| Scilex Pharmaceuticals INC. | $15.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Cotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.